Paradigm4 Launches Precision Medicine Platform for UK Biobank Data And Announces Industry-leading Adopters

is a groundbreaking international health resource with more
than 1.5 petabytes of data planned for collection and analysis: medical
records, genomic data, imaging, and measurements donated by 500,000 UK

newly launched REVEAL™ Translational Informatics Platform with its
PheGe™ Browser enables bioinformaticians and scientists to readily work
with the scale and diversity of public and proprietary multi-omics,
behavioral, clinical, health outcomes, and environmental data generated
today. Built on Paradigm4’s scientific data computational engine for
complex data analysis and machine learning, REVEAL™ accelerates
integrative, multi-modal, longitudinal, population-scale data science
exploration and discovery.

a global leader in RNAi therapeutics, has selected Paradigm4 as its
partner to exploit the power of the UK Biobank data. Paradigm4’s
REVEAL™ and PheGe™ software will help Alnylam to identify patient
cohorts based on medical records combined with advanced phenotype
technologies such as imaging and wearables to uncover genetic and
metabolic drivers of disease.

“The absolute scale and diversity of the data in the UK Biobank will
drive transformational GWAS/PheWAS research,” said Paradigm4’s CEO
Marilyn Matz. “Our aggressive timelines provide Alnylam—along with our
other top biopharma customers—with best-in-class performance and
services to rapidly mine this valuable data set.”

“The UK Biobank dataset redefines our view of Real World Evidence to
support active clinical development projects where new insights into
cohort selection for recruiting or stratifying patients are very
valuable,” added Zachary Pitluk, Ph.D., V.P. of Life Sciences. “The UK
Biobank data in REVEAL™ is a unique resource for in-silico trial
simulations with its ease of data selection and support for optimizing
machine learning parameters. Enabling customers with a truly private
analytical environment offers a distinct advantage in a competitive
market like drug development.”

About Paradigm4

a scientific information solutions provider, advances scientific and
engineering insights by enabling scientists and data scientists to take
full advantage of the scale, resolution, and diversity of public and
proprietary scientific data to accelerate their research. Leading Life
Sciences, IoT, instrument, and research institutes use Paradigm4’s
REVEAL™ discovery engine for collaborative, reproducible research. The
company was founded by renowned database researcher, Turing Award
laureate MIT Professor Michael